Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure

A diabetic patient with chronic renal failure who developed recurrent and prolonged episodes of hypoglycemia associated with use of sulfonylurea agent is presented here. This patient was hospitalized with neuroglycopenic symptoms of hypoglycemia that persisted in spite of large doses of parenteral g...

Full description

Saved in:
Bibliographic Details
Published in:International journal of artificial organs 2003-01, Vol.26 (1), p.86-89
Main Authors: Nzerue, C M, Thomas, J, Volcy, J, Edeki, T
Format: Article
Language:English
Subjects:
Adult
C-Peptide - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Gastrointestinal Agents - therapeutic use
Glipizide - adverse effects
Glipizide - therapeutic use
Humans
Hypoglycemia - chemically induced
Hypoglycemia - drug therapy
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Kidney Failure, Chronic - complications
Male
Octreotide - therapeutic use
Seizures - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A diabetic patient with chronic renal failure who developed recurrent and prolonged episodes of hypoglycemia associated with use of sulfonylurea agent is presented here. This patient was hospitalized with neuroglycopenic symptoms of hypoglycemia that persisted in spite of large doses of parenteral glucose replacement. On administration of somatostatin analogue octreotide, hypoglycemia resolved and, blood glucose levels were maintained even after cessation of parenteral glucose. The patient received 2 subcutaneous doses of octreotide 12 hours apart, and made a complete recovery. Our experience suggests that use of octerotide to treat refractory or prolonged sulfonylurea-included hypoglycemia in renal failure patients is safe and effective; large prospective studies would be needed to validate these findings.
ISSN:0391-3988
1724-6040
DOI:10.1177/039139880302600113